伦敦失去“市值一哥”？阿斯利康正谋划将上市地转至美国

Core Viewpoint - AstraZeneca is considering relocating its stock listing from London to the United States, which could significantly impact the UK stock market, already facing a series of delistings and missed IPO opportunities [1][2]. Group 1: Company Actions and Plans - AstraZeneca has a market capitalization of approximately £156 billion (around $213 billion) and has declined to comment on the potential relocation [2]. - The company has expressed dissatisfaction with the UK business investment environment, previously canceling a £450 million investment in a vaccine manufacturing facility in Northern England due to government support cuts [2]. - AstraZeneca is strengthening its ties with the US, planning to invest $3.5 billion in domestic manufacturing by the end of 2026 and rejoining major pharmaceutical lobbying groups after a two-year absence [2] [3]. Group 2: Market Impact and Revenue - The US is AstraZeneca's largest market, contributing about 42% of the company's revenue in the first quarter of this year [3]. - The potential move to the US listing aligns with the Trump administration's goal of attracting investment into the country, despite previous trade policy uncertainties [1].